Immucell (ICCC) Operating Leases (2020 - 2026)
Immucell's (ICCC) quarterly Operating Leases came in at $4.1 million in Q4 2025, down 0.82% YoY from $4.1 million in Q4 2024, and up 1.55% on a QoQ basis from $4.0 million in Q3 2025.
Immucell (ICCC) Operating Leases (2020 - 2026) Analysis & Trends
Immucell (ICCC) has 6 years of Operating Leases data on file, last reported at $4.1 million in Q4 2025.
- Quarterly Operating Leases fell 0.82% year-over-year to $4.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $4.1 million (down 0.82% YoY) and the FY2025 annual result came in at $4.1 million, down 0.82% from the prior year.
- Operating Leases advanced to $4.1 million in Q4 2025, from $4.0 million in the prior quarter.
- In the past five years, Operating Leases ranged from a high of $4.4 million in Q3 2023 to a low of $969077.0 in Q2 2022.
- A 5-year average of $2.9 million and a median of $4.0 million in 2024 frame the typical range for Operating Leases.
- Annual changes were most pronounced in 2022 — Operating Leases dropped 18.25% — and 2023, when it jumped 345.39%.
- Tracing ICCC's Operating Leases over 5 years: stood at $1.0 million in 2021, then soared by 115.88% to $2.2 million in 2022, then jumped by 83.87% to $4.1 million in 2023, then climbed by 1.28% to $4.1 million in 2024, then decreased by 0.82% to $4.1 million in 2025.
- The last three Operating Leases figures came in at $4.1 million (Q4 2025), $4.0 million (Q3 2025), and $4.1 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Immucell | 92.01 Mn | 83.15 Mn | 2.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.02 Mn |
| Dec 31, 2025 | 4.10 Mn |
| Sep 30, 2025 | 4.03 Mn |
| Jun 30, 2025 | 4.14 Mn |
| Mar 31, 2025 | 4.11 Mn |
| Dec 31, 2024 | 4.13 Mn |
| Sep 30, 2024 | 4.15 Mn |
| Jun 30, 2024 | 4.04 Mn |
| Mar 31, 2024 | 4.06 Mn |
| Dec 31, 2023 | 4.08 Mn |
| Sep 30, 2023 | 4.37 Mn |
| Jun 30, 2023 | 4.32 Mn |
| Mar 31, 2023 | 2.21 Mn |
| Dec 31, 2022 | 2.22 Mn |
| Sep 30, 2022 | 2.25 Mn |
| Jun 30, 2022 | 969,077.00 |
| Mar 31, 2022 | 1.11 Mn |
| Dec 31, 2021 | 1.03 Mn |
| Sep 30, 2021 | 1.16 Mn |
| Jun 30, 2021 | 1.19 Mn |